#1 Clinical Trials Search in Europe

Baricitinib

Baricitinib, also known by its brand name Olumiant, is a Janus kinase (JAK) inhibitor that has been the subject of numerous clinical trials for various medical conditions. This article explores the use of Baricitinib in clinical trials for rheumatoid arthritis, cutaneous lichen planus, Alzheimer’s disease, amyotrophic lateral sclerosis, pyoderma gangrenosum, and other conditions. We’ll examine the drug’s efficacy, safety profile, and potential benefits for patients with these diverse health issues.

Table of Contents

What is Baricitinib?

Baricitinib is a medication used to treat various inflammatory conditions. It is known by several names, including Olumiant, INCB028050, and LY3009104[1]. Baricitinib belongs to a class of drugs called Janus kinase (JAK) inhibitors, specifically targeting JAK1 and JAK2[2]. These enzymes play a crucial role in the body’s immune response and inflammation processes.

How Does Baricitinib Work?

Baricitinib works by inhibiting the action of JAK1 and JAK2 enzymes. This inhibition helps to reduce the release of certain chemicals in the body that cause inflammation. By doing so, baricitinib can help decrease pain, swelling, and other symptoms associated with inflammatory conditions[2]. Additionally, some research suggests that baricitinib may reduce the entry of viruses into cells, which is why it has been studied for use in COVID-19 treatment[2].

Conditions Treated with Baricitinib

Baricitinib has been studied and used for several conditions, including:

  • Rheumatoid Arthritis (RA): This is a chronic inflammatory disorder affecting the joints. Baricitinib is approved for treating moderate to severe RA in patients who haven’t responded well to other treatments[3].
  • COVID-19: During the pandemic, baricitinib received emergency use authorization for treating certain hospitalized COVID-19 patients[2].
  • Cutaneous Lichen Planus: This is a condition causing itchy, inflamed rashes on the skin. Research is ongoing to evaluate baricitinib’s effectiveness in treating this condition[4].
  • Alzheimer’s Disease (AD) and Amyotrophic Lateral Sclerosis (ALS): Studies are investigating the potential of baricitinib in treating these neurodegenerative diseases[1].
  • Pyoderma Gangrenosum (PG): This is a rare skin condition causing large, painful sores. Research is being conducted on baricitinib’s effectiveness in treating PG[5].
  • Idiopathic Granulomatous Mastitis: This is a rare inflammatory breast disease. Studies are exploring baricitinib’s potential in treating this condition[6].

Dosage and Administration

Baricitinib is typically taken orally in tablet form. The dosage can vary depending on the condition being treated and the individual patient’s needs. Some common dosages include:

  • For Rheumatoid Arthritis: 2 mg or 4 mg once daily[3]
  • For COVID-19: 4 mg once daily[2]
  • For research in other conditions: Dosages may range from 2 mg to 4 mg daily, often starting with a lower dose and increasing if needed[4][1]

It’s important to note that baricitinib should only be taken under the guidance of a healthcare professional, as they will determine the appropriate dosage based on your specific condition and health status.

Effectiveness of Baricitinib

The effectiveness of baricitinib has been demonstrated in several studies:

  • For Rheumatoid Arthritis: Studies have shown that a significant percentage of patients achieve improvement in their symptoms, as measured by standard scales like the American College of Rheumatology (ACR) criteria and the Disease Activity Score (DAS28)[3].
  • For COVID-19: Research has indicated that baricitinib may help reduce the severity of symptoms and improve recovery time in certain hospitalized patients[2].
  • For other conditions: Studies are ongoing to determine the effectiveness of baricitinib in treating various inflammatory and neurodegenerative diseases[4][1][5][6]

Potential Side Effects

Like all medications, baricitinib can cause side effects. Some potential side effects include:

  • Upper respiratory tract infections
  • Nausea
  • Herpes simplex
  • Urinary tract infections
  • Increased cholesterol levels

More serious but less common side effects may include an increased risk of certain infections, blood clots, and changes in blood cell counts. It’s important to discuss potential side effects with your healthcare provider and report any unusual symptoms you experience while taking baricitinib[7].

Ongoing Research

Baricitinib continues to be the subject of numerous clinical trials exploring its potential in treating various conditions. Some areas of ongoing research include:

  • Its effectiveness in treating neurodegenerative diseases like Alzheimer’s and ALS[1]
  • Its potential in treating skin conditions like cutaneous lichen planus and pyoderma gangrenosum[4][5]
  • Its use in treating rare inflammatory conditions like idiopathic granulomatous mastitis[6]

These ongoing studies aim to further understand the drug’s mechanisms of action, its effectiveness in different conditions, and its long-term safety profile. As research progresses, we may see baricitinib being used to treat a wider range of conditions in the future.

Condition Study Phase Dosage Duration Key Outcomes Measured
Rheumatoid Arthritis Phase 2 1 mg, 2 mg, 4 mg, 7 mg, 10 mg daily 12-64 weeks ACR20 response, DAS28 scores, HAQ-DI, safety profile
Cutaneous Lichen Planus Not specified 2 mg daily for 16 weeks, then 4 mg daily for 12 weeks 28 weeks Physician Global Assessment, Modified CAILS score, pruritus
Alzheimer’s Disease and ALS Phase 1/2 2 mg daily for 8 weeks, then 4 mg daily for 16 weeks 24 weeks CSF drug concentration, inflammatory biomarkers, safety
Pyoderma Gangrenosum Phase 2 4 mg daily 24 weeks Ulcer healing, Physician Global Assessment, quality of life
Idiopathic Granulomatous Mastitis Not specified 2 mg daily Up to 24 months Clinical remission rate, lesion diameter, inflammation markers

FAQ

  • What is Baricitinib and how does it work? Baricitinib is a Janus kinase (JAK) inhibitor that works by blocking specific enzymes involved in inflammation. It is primarily used to treat rheumatoid arthritis and has been studied for its potential in treating other inflammatory and autoimmune conditions.
  • What medical conditions are being studied with Baricitinib in clinical trials? Clinical trials are exploring Baricitinib's potential in treating various conditions, including rheumatoid arthritis, cutaneous lichen planus, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), pyoderma gangrenosum, and idiopathic granulomatous mastitis.
  • What are some common dosages of Baricitinib used in clinical trials? Clinical trials have studied various dosages of Baricitinib, typically ranging from 1 mg to 10 mg daily. Common dosages include 2 mg, 4 mg, and 7 mg taken orally once daily. The specific dosage may vary depending on the condition being treated and the study design.
  • What are some potential side effects of Baricitinib? While side effects can vary, some potential adverse reactions to Baricitinib may include upper respiratory tract infections, nausea, and changes in blood cell counts. Clinical trials closely monitor participants for any adverse events to ensure patient safety.
  • How long do clinical trials for Baricitinib typically last? The duration of clinical trials for Baricitinib can vary widely depending on the study design and condition being treated. Some trials last for 12 to 24 weeks, while others may extend up to 64 weeks or longer to assess long-term efficacy and safety.

Ongoing Clinical Trials on Baricitinib

  • A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium Czechia Finland France Germany Italy +6

  • A Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium Finland France Germany Italy The Netherlands +5

  • Study of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study of baricitinib versus placebo for treating polymyalgia rheumatica in adult patients

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Immune Response to Recombinant Zoster Vaccine in Rheumatic Disease Patients Using Baricitinib, Tofacitinib, or Methotrexate

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Baricitinib for Patients with Relapsing or Naïve Dermatomyositis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Baricitinib for Patients with Calcium Pyrophosphate Deposition Disease (CPPD) Using Methotrexate Sodium and Drug Combination

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Italy Poland +1

  • Study of Baricitinib and Adalimumab for Children Aged 2 to 17 with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Spain

  • Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Croatia Czechia Estonia France Germany +7

Glossary

  • Janus kinase (JAK) inhibitor: A type of medication that works by blocking specific enzymes called Janus kinases, which are involved in the body's immune response and inflammation processes.
  • Rheumatoid arthritis (RA): A chronic inflammatory disorder that primarily affects the small joints of the hands and feet, causing pain, swelling, and stiffness.
  • Cutaneous lichen planus: An inflammatory condition that affects the skin, causing itchy, flat-topped bumps or lesions.
  • Amyotrophic lateral sclerosis (ALS): A progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control.
  • Pyoderma gangrenosum: A rare skin condition that causes large, painful sores (ulcers) to develop on the skin, most often on the legs.
  • Idiopathic granulomatous mastitis: A rare, benign inflammatory breast disease of unknown cause that can mimic breast cancer.
  • ACR20 response: A measure used in rheumatoid arthritis clinical trials, indicating a 20% improvement in tender and swollen joint counts, as well as 3 of 5 other criteria.
  • Disease Activity Score 28 (DAS28): A measure of disease activity in rheumatoid arthritis, based on an examination of 28 joints, along with other clinical and laboratory measures.
  • C-reactive protein (CRP): A protein produced by the liver in response to inflammation, often used as a marker of disease activity in various conditions.
  • Erythrocyte sedimentation rate (ESR): A blood test that measures how quickly red blood cells settle in a test tube, which can indicate the level of inflammation in the body.

References

  1. https://clinicaltrials.gov/study/NCT05189106
  2. https://clinicaltrials.gov/study/NCT04358614
  3. https://clinicaltrials.gov/study/NCT00902486
  4. https://clinicaltrials.gov/study/NCT05188521
  5. https://clinicaltrials.gov/study/NCT04901325
  6. https://clinicaltrials.gov/study/NCT05852171
  7. https://clinicaltrials.gov/study/NCT01469013